Can Dash Bio’s $30m automation bet break one of drug development’s slowest bottlenecks?
Dash Bio’s $30 million Series A backs automated bioanalysis expansion, but validation, scale and sponsor adoption will determine its impact.
Medical Devices & Diagnostics
Pharma & Biotech
Is mRNA-1010 the breakthrough Moderna needs beyond COVID-19 vaccines?
Moderna’s mRNA-1010 has cleared a major regulatory hurdle, but evidence in older adults, higher reactogenicity and seasonal contracting could limit its early impact.
Pharma & Biotech
Can Moderna turn hantavirus urgency into a credible rare-virus vaccine strategy?
Moderna surged on hantavirus hopes. The real test is whether rare-virus urgency can become a viable mRNA vaccine pathway.
Pharma & Biotech
Moderna and Merck’s mRNA-4157 combo shows durable benefit in resected high-risk melanoma
Moderna, Inc. and Merck have reported five-year follow-up results from the Phase 2b KEYNOTE-942 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized mRNA-based neoantigen therapy, in combination with pembrolizumab (KEYTRUDA) in patients with resected high-risk stage III or IV melanoma. The combination demonstrated a 49 percent reduction in the risk of recurrence or
Features & Analysis
Why are “retired proteins” the hottest new targets in cancer immunotherapy research?
Few ideas have captivated both the scientific imagination and biotech investment flows quite like the cancer vaccine. For decades, the industry narrative was full of hope—and disappointment. The graveyard of failed trials stretches from Dendreon’s Provenge to once-hyped peptide and dendritic cell platforms. For every announcement of an “immune breakthrough,” there seemed to be a